• 1
    Hsing AW, Devesa SS. Trends and patterns of prostate cancer: what do they suggest Epidemiol Rev 2001; 23: 313.
  • 2
    International Agency for Research on Cancer (IARC). Cancer incidence in five continents. vol VII. Lyon (France): IARC; 1997. p. 668, 383–405, 872–3.
  • 3
    Barnes S. Role of phytochemicals in prevention and treatment of prostate cancer. Epidemiol Rev 2001; 23: 1025.
  • 4
    Adlercreutz H. Phyto-oestrogens and cancer. Lancet Oncol 2002; 3: 36473.
  • 5
    Stattin P, Adlercreutz H, Tenkanen L, Jellum E, Lumme S, Hallmans G, Harvei S, Teppo L, Stumpf K, Luostarinen T, Lehtinen M, Dillner J, Hakama M. Circulating enterolactone and prostate cancer risk: a Nordic nested case-control study. Int J Cancer 2002; 99: 1249.
  • 6
    Akaza H, Miyamaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002; 32: 296300.
  • 7
    Hsing AW. Hormones and prostate cancer: what's next Epidemiol Rev 2001; 23: 4258.
  • 8
    Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000; 18: 84753.
  • 9
    Ohno Y, Tamakoshi A, the JACC Study Group Japan. Collaborative cohort study for evaluation of cancer risk sponsored by Monbusho (JACC Study). J Epidemiol 2001; 11: 14450.
  • 10
    World Health Organization (WHO). International statistical classification of diseases and related health problems. 10th Rev. vol I. Geneva ( Switzerland ) : WHO; 1992.
  • 11
    Coward L, Kirk M, Nicolas A, Stephen B. Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry. Clin Chim Acta 1996; 247: 12142.
  • 12
    Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, Mazur W, Wähälä K, Adlercreutz H. Pharmacokinetics of soybean isoflavones in plasma, urine, and feces of men after ingestion of 60 g baked soybean powder (kinako). J Nutr 1998; 128: 17105.
  • 13
    Lampe JW, Skor HE, Li S, Wähälä K, Howald WN, Chu C. Wheat bran and soy protein feeding do not alter urinary excretion of the isoflavan equol in premenopausal women. J Nutr 2001; 131: 7404.
  • 14
    Setchell KDR, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002; 132: 357784.
  • 15
    Catalona WJ, Richie JP, Ahmann RR, Hudson MA, Scardino PT, Flanigan RC, de Kernion JB, Ratliff TL, Kavoussi LR, Dalkin RL, Waters WB, MacFarlane MT, Southwick PC. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151: 128390.
  • 16
    Nakagawa S, Watanabe M, Nomoto T, Sugimoto K, Mikami K, Ebisui K, Kitamura K, Kojima M, Saitoh M, Watanabe H. Mass screening for prostate cancer. Acta Urol Jpn 1997; 43: 44752.
  • 17
    Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, Yang N. Prostate specific antigen in the diagnosis and treatment of adenocar-cinoma of the prostate. II. Radical prostatectomy treated patients. J Urol 1989; 141: 107683.
  • 18
    Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, Walsh PC. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 1990; 143: 74752.
  • 19
    Shida K, Koyanagi T, Kumamoto Y, Ohori T, Suzuki K, Origas S, Yamanaka H, Koiso K, Shimazaki J, Hosaka M, Sato S, Katayama T, Takeuchi H, Miyake K, Tomoyoshi T, Watanabe H, Goto H, Ohmori H, Tanaka H, Fujita Y, Kumazawa J, Sakamoto K, Saito Y, Ikegami K, Kuriya N. Clinical evaluation of TZP-61 on benign prostatic hypertophy, a double-blind comparative study with Prostal® 25. Rinsho Iyaku 1988; 4: 114564 (in Japanese).
  • 20
    Itoh N, Kumamoto Y, Akagashi K, Murata H, Tsukamoto T, Umehara T, Mikuma N, Yamaguchi Y, Nanbu A, Suzuki N. The assessment of bioavailable androgen levels from the serum free testosterone level. Jpn J Endocrinol 1991; 67: 2332.
  • 21
    WalshPC (ed). Endocrine control of prostate growth. In: Campbell's urology. 8th ed. Philadelphia ( PA ) : Saunders; 2002. p. 12458.
  • 22
    Breslow NE, Day NE. Statistical methods in cancer research. vol I. Lyon ( France ) : IARC; 1980. p. 24779.
  • 23
    Lampe JW, Gstafson DR, Hutchins AM, Martini MC, Li Sue, Wähälä K, Grantis GA, Potter JD, Slavin JL. Urinary isoflavonoid and lignan excretion on a Western diet: relation to soy, vegetable, and fruit intake. Cancer Epidemiol Biomarkers Prev 1999; 8: 699707.
  • 24
    Madersbacher S, Schatzl G, Bieglmayer C, Reiter WJ, Gassner C, Berger P, Zidek T, Marberger M. Impact of radical prostetectomy and TURP on the hypothalamic-gonadal hormone axis. Urology 2002; 60: 86974.
  • 25
    Nagata C, Inaba S, Kawakami N, Kakizoe T, Shimizu H. Inverse association of soy product intake with serum androgen and estrogen concentrations in Japanese men. Nutr Cancer 2000; 36: 148.
  • 26
    Nagata C, Takatsuka N, Shimizu H, Hayashi H, Akamatsu T, Murase K. Effect of soymilk consumption on serum estrogen and androgen concentration in Japanese men. Cancer Epidemiol Biomarkers Prev 2001; 10: 17984.
  • 27
    Coldham NG, Dave M, Sivapathasundaram S, McDonnell DP, Conner C, Sauer MJ. Evaluation of recombinant yeast cell estrogen screening assay. Environ Health Perspect 1997; 105: 73442.
  • 28
    Breinholt V, Larsen JC. Detection of weak estrogenic flavonoids using a recombinant yeast strain and a modified MCF7 cellproliferation assay. Chem Res Toxicol 1998; 11: 6229.
  • 29
    Morito K, Morito K, Hirose T, Kinjo J, Hirakawa T, Okawa M, Nohara T, Ogawa S, Inoue S, Muramatsu M, Masamune Y. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull 2001; 24: 3516.
  • 30
    Markiewicz L, Gary J, Adlercreutz, Grpide E. In vitro bioassays of non–steroidal phytoestrogens. J Steroid Biochem Mol Biol 1993; 45: 399405.
  • 31
    Hedlund TE, Johannes WU, Miller GJ. Soy isoflavonoid equol modulates the growth of benign and malignant prostatic epithelial cells in vitro. Prostate 2003; 54: 6878.
  • 32
    Duncan AM, Merz-Demlow BE, Xu X, Phipps WR, Kurzer MS. Premenopausal equol excretors show plasma hormone profiles associated with lowered risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2000; 9: 5816.
  • 33
    Izumi T, Piskula MK, Osawa S, Obata A, Tobe K, Saito M, Kataoka S, Kubota Y, Kikuchi M. Soy isoflavone aglycones are absorbed faster and in higher amounts than their glucosides in humans J Nutr 2000; 130: 16959.
  • 34
    Yamamoto S, Sobue T, Sasaki S, Kobayashi M, Arai Y, Uehara M, Adlercreutz H, Watanabe S, Takahashi T, Iitoi Y, Iwase Y, Akabane M, Tsugane S. Validity and reproducibility of a self-administered food-frequency questionnaire to assess isoflavone intake in a Japanese population in comparison with dietary records and blood and urine isoflavones. J Nutr 2001; 131: 27417.
  • 35
    Morton MS, Arisaka O, Miyake N, Morgan LD, Evans BA. Phytoestrogen concentrations in serum from Japanese men and women over forty years of age. J Nutr 2002; 132: 316871.